Abbott Laboratories
Abbott Laboratories (USA) holds 2 active US FDA Type II Drug Master Files and 34 inactive, has DMF or CEP filings on record for 19 active ingredients and is linked to 3 FDA-registered manufacturing sites. 8 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Abbott Laboratories: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/abbott-laboratories
Overview
Abbott Laboratories, a global healthcare company, focuses on the research and development, manufacture, and sale of a broad and diversified line of health care products. It operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Core services & business areas
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Abbott Laboratories holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Abbott Laboratories holds 2 active (36 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- LACTULOSE CONCENTRATE USPActive1993-03-19
- VERAPAMIL HYDROCHLORIDEActive1987-06-04
- HYDROCODONE/ACETAMINOPHEN EXTENDED RELEASE TABLETSInactive2006-08-04
- FENOFIBRATE SPRAY GRANULATION INTERMEDIATEInactive2003-10-10
- AMIKACIN SULFATEInactive1998-09-01
- CLINDAMYCIN HYDROCHLORIDEInactive1998-09-01
- BUTORPHANOL TARTRATE USPInactive1998-03-27
- TROMETHAMINE,USPInactive1997-08-29
- SIMETHICONE COATED CELLULOSE (SONORX); MANFACTURED IN NORTH CHICAGO, ILInactive1996-08-20
- D-CHIRO-INOSITOLInactive1996-06-28
- MSI-78Inactive1995-07-07
- ATRACURIUM BESYLATEInactive1994-10-21
- AMRINONEInactive1994-09-14
- SEMI-WORKS AREA IN QUEENBOROUGH, KENT, UNITED KINGDOMInactive1993-05-28
- PROTIRELIN (TRH)Inactive1993-05-14
- FACILITIES AND OPERATING PROCEDURES IN LATINA, ITALY (LABORATORI ABBOTT S.P.A.)Inactive1993-04-17
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ETHRANE IN QUEENBOUROUGH, KENT, ENGLAND.Inactive1993-03-23
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN NORTH CHICAGO, ILLINOIS.Inactive1992-05-29
- GLIPIZIDEInactive1991-10-22
- 9-(S)-ERYTHROMYCYLAMINEInactive1991-07-30
- ARBUTAMINEInactive1991-05-31
- FACILITIES AND OPERATING PROCEDURES IN QUEENBOROUGH, ENGLANDInactive1991-04-29
- FENTANYLInactive1991-03-18
- RAPAMYCIN CRUDE OILInactive1991-01-02
- DOBUTAMINE HYDROCHLORIDEInactive1990-06-05
- HYROCHLOROQUINE SULFATEInactive1990-03-22
- PENTAMIDINE ISETHIONATEInactive1989-08-15
- FACILITIES LOCATED IN QUEENBOROUGH, KENT, UKInactive1989-05-16
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN QUEENBOURGH, KENT, UNITED KINGDOM.Inactive1989-03-01
- ETHRANE (ENFLURANE)Inactive1986-04-23
- METHYLPREDNISOLONE HEMISUCCINATEInactive1985-09-03
- VERAPAMIL AS MNFG IN N.CHICAGO, ILLINOISInactive1983-03-31
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MCPHERSON, KANSAS.Inactive1977-02-16
- ESTERIFIED ESTROGENS USPInactive1976-11-02
- SUCCINYLCHOLINE CHLInactive1971-11-17
- 2-(2-FORMYLHYDRAZINO)-4-(5-NITRO-2-FURYL)-THIAZOLE (AS-L7665)&A-2L203Inactive1963-08-08
Registered manufacturing sites (3)
Physical sites registered with the US FDA and resolved to Abbott Laboratories, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
8 FDA enforcement records linked to this company.
- recall — Class II2013-01-09
Labeling: Error on Declared Strength. Product labeled to contain 150 mcg tablets actually contained 75 mcg tablets.
- recall — Class II2012-10-03
Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.
- recall — Class II2012-10-03
Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.
- recall — Class II2012-10-03
Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.
- recall — Class II2012-06-27
CGMP Deviations: There is potential that Abbott's third party manufacturer, Hospira, may have applied a foreign (incorrect) stopper to vials in a specific lot of Zemplar Injection.
- 4832011-07-15
Complaint Handling Procedure
- 4832010-12-16
Failure by applicant to report ADE
- warning_letter2009-07-14
FDA Warning Letter (drug product)
Is this Abbott Laboratories?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.